Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292743 · ClinicalTrials.gov registry record · Phase 1
Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04292743 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 19 participants.
The verdict
NCT04292743, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX. We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil \[5-FU\], leucovorin, irinotecan, and oxaliplatin) will be safe and demonstrate preliminary signs of efficacy in patients with advanced pancreatic cancer. Safety assessments include adverse events, physical examination abnormalities, vital signs, and clinical laboratory tests (including blood chemistry, hematology, and coagulation panel).
Interventions
- DRUG FOLFIRINOX
- BIOLOGICAL Eryaspase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292743
The ClinicalTrials.gov registry entry for NCT04292743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFIRINOX is the first listed.
NCT04292743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04292743 about?
NCT04292743 is a clinical study titled "Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma". This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX. We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil ...
What is the current status of trial NCT04292743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-12-02. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT04292743?
The interventions under investigation include: FOLFIRINOX (DRUG), Eryaspase (BIOLOGICAL).
Who is sponsoring clinical trial NCT04292743?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.